心房細動のトータルマネジメント

出版社： 文光堂
著者：
発行日： 2014-03-10
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784830619229
電子書籍版： 2014-03-10 （第1版第5刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

8,140 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

8,140 円(税込)

購入する

商品紹介

心房細動は最もありふれた不整脈である．従来より不整脈をどう治療するかに関心が向けられていたが，決して心房細動患者の生命予後は良くないことがわかってきた．しかし昨今新しい抗凝固薬が出されたことにより，心原性脳塞栓症を予防し，生命予後の改善をする基盤が整いつつある．本書では，抗不整脈薬を漫然と使うことを避け，「脈のコントロールから生命予後の改善へ」を治療姿勢として，心房細動のトータルマネジメントを行うための考え方や方法をまとめた．

目次

  • 心房細動のトータルマネジメント

    ―目次―

    I はじめに─心房細動診療の常識が変わった！─

    II 治療の常識が変わった！
    　A． 抗凝固療法は必須─では具体的にどうする？─
    　B． レートコントロールは心房細動治療の基礎である
    　C． カテーテルアブレーションを有効に活用する
    　D． 抗不整脈薬によるリズムコントロールは限定的
    　E． 心房細動の原因を治療し予防しよう

    III 知っておくべき心房細動の知識あれこれ
    　A． 心房細動の分類とその意義
    　B． 心房細動の合併症は血栓だけではない
    　C． 心房細動患者にするべき検査とその意義

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I はじめに - 心房細動診療の常識が変わった ! -

P.9 掲載の参考文献
1) Inoue, H et al : Prevalence of atrial fibrillation in the general population of Japan : an analysis based on periodic health examination. Int J Cardiol 2009 ; 137 : 102-107
 
2) Hobbs, FD et al : A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess 2005 ; 9 : 1-74
 
3) Wolf, PA et al : Secular trends in the prevalence of atrial fibrillation : the Framingham Study. Am Heart J 1996 ; 131 : 790-795
 
4) Friberg, J et al : Sex-specific increase in the prevalence of atrial fibrillation (The Copenhagen City Heart Study). Am J Cardiol 2003 ; 92 : 1419-1423
 
5) Benjamin, EJ et al : Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994 ; 271 : 840-844
 
6) Lloyd-Jones, DM et al : Lifetime risk for development of atrial fibrillation : the Framingham Heart Study. Circulation 2004 ; 110 : 1042-1046
 
7) Benjamin, EJ et al : Impact of atrial fibrillation on the risk of death. The Framingham Heart Study. Circulation 1998 ; 98 : 946-952
 
8) Hart, RG et al : Meta-analysis : antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007 ; 146 : 857-867
 
9) Gage, BF et al : Validation of clinical classification schemes for predicting stroke : results from the national registry of atrial fibrillation. JAMA 2001 ; 285 : 2864-2870
 
10) Lip, GY et al : Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach : the Euro Heart survey on atrial fibrillation. Chest 2010 ; 137 : 263-272
 
11) Lip, GY et al : Identifying patients at high risk for stroke despite anticoagulation : a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010 ; 41 : 2731-2738
 
12) Camm, AJ et al : Guidelines for the management of atrial fibrillation : the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010 ; 31 : 2369-2429
 
13) The AFFIRM investigators : Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004 ; 109 : 1509-1513
 
14) Wyse, DG et al : A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 ; 347 : 1825-1833
 
15) Krahn, AD et al : The natural history of atrial fibrillation : incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995 ; 98 : 476-484
 
16) Lip, GY et al : Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J 2007 ; 28 : 752-759
 
17) 脳卒中合同ガイドライン委員会編 : 脳卒中治療ガイドライン 2009, 協和企画, 東京, 2009, 21-22, 31-33
 

II 治療の常識が変わった !

P.15 掲載の参考文献
1) 峰松一夫ほか : 脳血管障害の分類と診断. 脳卒中診療ハンドブック, 峰松一夫編著, 中外医学社, 東京, 1998, 43-46
 
2) Kubo, M et al : Decreasing incidence of lacunar vs other types of cerebral infarction in a japanese population. Neurology 2006 ; 66 : 1539-1544
 
3) Kimura, K et al : Atrial fibrillation as a predictive factor for severe stroke and early death in 15,831 patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry 2005 ; 76 : 679-683
 
4) 荒木信夫ほか : 急性期脳卒中の実態 1病型別・年代別頻度- 欧米・アジアとの比較. 脳卒中データバンク 2009, 小林祥泰編, 中山書店, 東京, 2009, 22-24
 
5) De Wit, L et al : Five-year mortality and related prognostic factors after inpatient stroke rehabilitation : a European multi-centre study. J Rehabil Med 2012 ; 44 : 547-552
 
6) van Swieten, JC et al : Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988 ; 19 : 604-607
 
7) 厚生労働統計協会 : 全国人口の動向. 国民衛生の動向・厚生の指標 2012 ; 59 : 42-47
 
P.19 掲載の参考文献
1) Olesen, JB et al : Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation : nationwide cohort study. BMJ 2011 ; 342 : d124
PubMed
2) Olesen, JB et al : The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1 : a nationwide cohort study. Thromb Haemost 2012 ; 107 : 1172-1179
 
3) Taillandier, S et al : Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score=0 in a community-based cohort study. J Cardiovasc Electrophysiol 2012 ; 23 : 708-713
 
4) Komatsu, T et al : Relationship between CHA2DS2-VASc scores and ischemic stroke/cardiovascular events in Japanese patients with paroxysmal atrial fibrillation not receiving anticoagulant therapy. J Cardiol 2012 ; 59 : 321-328
 
5) Coppens, M et al : The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J 2013 ; 34 : 170-176
 
6) Friberg, L et al : Assessment of female sex as a risk factor in atrial fibrillation in Sweden : nationwide retrospective cohort study. BMJ 2012 ; 344 : e3522
PubMed
7) Hijazi, Z et al : N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation : insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol 2013 ; 61 : 2274-2284
 
8) Hijazi, Z et al : High sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol 2014 ; 63 : 52-61
PubMed
P.21 掲載の参考文献
1) Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994 ; 154 : 1449-1457
 
2) Gage, BF et al : Validation of clinical classification schemes for predicting stroke : results from the National Registry of Atrial Fibrillation. JAMA 2001 ; 285 : 2864-2870
 
3) Inoue, H et al : Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation. Circ J 2006 ; 70 : 651-656
 
4) Camm, AJ et al : Guidelines for the management of atrial fibrillation : the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010 ; 31 : 2369-2429
 
5) Olesen, JB et al : Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation : nationwide cohort study. BMJ 2011 ; 342 : d124
PubMed
6) Atarashi, H et al : Present status of anticoagulation treatment in Japanese patients with atrial fibrillation. a report from the J-RHYTHM Registry. Circ J 2011 ; 75 : 1328-1333
 
7) Friberg, L et al : Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation : the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012 ; 33 : 1500-1510
 
P.23 掲載の参考文献
1) JCS Joint Working Group : Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008) : digest version. Circ J 2010 ; 74 : 2479-2500
 
2) Hart, RG et al : Meta-analysis : antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007 ; 146 : 857-867
 
3) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993 ; 342 : 1255-1262
 
4) ACTIVE Writing Group on behalf of the ACTIVE Investigators : Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W) : a randomised controlled trial. Lancet 2006 ; 367 : 1903-1912
 
5) The ACTIVE investigators : Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009 ; 360 : 2066-2078
 
6) Sato, H et al : Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation. Japan Atrial Fibrillation Stroke Trial. Stroke 2006 ; 37 : 447-451
 
P.31 掲載の参考文献
1) Watson, T et al : Mechanisms of thrombogenesis in atrial fibrillation : Virchow's triad revisited. Lancet 2009 ; 373 : 155-166
 
2) 丸山征郎 : 抗凝固療法の基礎. 臨と研 2013 ; 90 : 1186-1190
 
3) Gage, BF et al : Validation of clinical classification schemes for predicting stroke : results from the National Registry of Atrial Fibrillation. JAMA 2001 ; 285 : 2864-2870
 
4) 浦野哲盟ほか : 血栓形成と凝固・線溶 治療に生かせる基礎医学. メディカル・サイエンス・インターナショナル, 東京, 2013
 
5) Sekiya, F et al : Localization of the specific binding site for magnesium (II) ions in factor IX. FEBS Lett 1996 ; 392 : 205-208
 
6) Mann, KG et al : Surface-dependent hemostasis. Semin Hematol 1992 ; 29 : 213-226
 
7) 相澤万象ほか : 活性化第X因子とXa阻害薬の作用. 循環器内科医のためのXa阻害薬のすべて, メディカルレビュー社, 大阪, 2012, 105-113
 
8) 福江英尚ほか : 第XIII因子Aサブユニット欠損症. 血栓止血誌 2001 ; 12 : 66-73
 
9) 鈴木宏治 : 血液製剤輸血の適応と使用法 3. トロンボモジュリン製剤 : リコモジュリン. 血栓止血誌 2009 ; 20 : 9-11
 
10) 尾崎由基男 : 血栓症を血液検査で診断する-血栓形成のマーカー-. Medicina 2004 ; 41 : 936-938
 
11) 浦野哲盟 :線溶機序. 脈管学 2011 ; 51 : 293-299
 
12) 小嶋哲人 : 抗Xa 薬の特徴は? 循環器内科 2011 ; 69 : 130-135
 
13) 山下武志 : Old and New 心房細動の抗凝固療法. メディカルサイエンス, 東京, 2012
 
14) 笠井宏樹ほか : 経口抗凝固薬の適正使用 わかりやすい血栓と止血の臨床. 南江堂, 東京, 2011, 210-213
 
15) Stangier, J et al : The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007 ; 64 : 292-303
 
P.38 掲載の参考文献
1) Suzuki, S et al : Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time. Circ J 2012 ; 76 : 755-757
 
2) Connolly, SJ et al : Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 ; 361 : 1139-1151
 
3) Connolly, SJ et al : Newly identified events in the RE-LY trial. N Engl J Med 2010 ; 363 : 1875-1876
 
4) Hori, M et al : Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--subanalysis in Japanese population in RE-LY trial. Circ J 2011 ; 75 : 800-805
 
5) Eikelboom, JW et al : Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation : an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011 ; 123 : 2363-2372
 
6) Furie, KL et al : Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation : a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012 ; 43 : 3442-3453
 
P.46 掲載の参考文献
1) Schirmer, SH et al : Novel anticoagulants for stroke prevention in atrial fibrillation : Current clinical evidence and future developments. J Am Coll Cardiol 2010 ; 56 : 2067-2076
 
2) Patel, MR et al : Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011 ; 365 : 883-891
 
3) Hori, M et al : Rivaroxaban vs. warfarin in japanese patients with atrial fibrillation-the J-ROCKET AF study. Circ J 2012 ; 76 : 2104-2111
 
4) Mahaffey, KW et al : End of study transition from study drug to open-label vitamin K antagonist therapy : The ROCKET AF experience. Circ Cardiovasc Qual Outcomes 2013 ; 6 : 470-478
 
5) JCS Joint Working Group : Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008) : digest version. Circ J 2010 ; 74 : 2479-2500
 
6) Granger, CB et al : Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011 ; 365 : 981-992
 
7) Lopes, RD et al : Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation : a secondary analysis of a randomised controlled trial. Lancet 2012 ; 380 : 1749-1758
 
8) Connolly, SJ et al : Apixaban in patients with atrial fibrillation. N Engl J Med 2011 ; 364 : 806-817
 
9) Cockcroft, DW et al : Prediction of creatinine clearance from serum creatinine. Nephron 1976 ; 16 : 31-41
 
10) Eerenberg, ES et al : Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate : a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011 ; 124 : 1573-1579
 
11) Lu, G et al : A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013 ; 19 : 446-451
 
P.48 掲載の参考文献
1) Connolly, SJ et al : Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 ; 361 : 1139-1151
 
2) Patel, MR et al : Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011 ; 365 : 883-891
 
3) Granger, CB et al : Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011 ; 365 : 981-992
 
4) 小嶋哲人 : 経口抗凝固薬療法の新時代. 血液フロンティア 2012 ; 22 : 1041-1044
 
5) 小嶋哲人 : 頭蓋内出血に対する新規抗凝固療法の作用 ; 心房細動患者の脳卒中予防に対する無作為割り付けワルファリン対照試験結果 (RE-LY試験) と凝固カスケードからの考察. Pharm Med 2011 ; 29 : 129-134
 
6) Eikelboom, JW et al : Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation : an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011 ; 123 : 2363-2372
 
7) van Ryn, J et al : Dabigatran etexilate -- a novel, reversible, oral direct thrombin inhibitor : interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010 ; 103 : 1116-1127
 
8) Miyamoto, K et al : Efficacy and safety of novel anticoagulant dabigatran in clinical practice for Japanese patients with nonvalvular atrial fibrillation. J Arrhythmia 2013 (in press)
 
9) Asmis, LM et al : Quantification by anti-FXa assay and influence on coagulation tests A study in 9 Swiss laboratories. Thromb Res 2012 ; 129 : 492-498
 
10) Toyoda, K et al : Blood pressure levels and bleeding events during antithrombotic therapy : The Bleeding with Antithrombotic Therapy (BAT) study. Stroke 2010 ; 41 : 1440-1444
 
P.50 掲載の参考文献
1) Giugliano, RP et al : Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013 ; 369 : 2093-2104
 
2) Ruff, CT et al : Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials. Lancet 2013, in press
 
P.56 掲載の参考文献
1) Connolly, SJ et al : Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 ; 361 : 1139-1151
 
2) Connolly, SJ et al : Newly identified events in the RE-LY trial. N Engl J Med 2010 ; 363 : 1875-1876
 
3) Patel, MR et al : Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011 ; 365 : 883-891
 
4) Granger, CB et al : Apixaban versus warfarin in patients with atrial fibriallation. N Engl J Med 2011 ; 365 : 981-992
 
5) Singer, DE et al : The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009 ; 151 : 297-305
 
6) Gage, BF et al : Validation of clinical classification schemes for predicting stroke : results from the National Registry of Atrial Fibrillation. JAMA 2001 ; 285 : 2864-2870
 
7) Van de Werf F et al : A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves : The Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J 2012 ; 163 : 931-937
 
P.58 掲載の参考文献
1) John, A et al : Which oral anticoagulant for which atrial fibrillation patient : recent clinical trial s and evidence-based choices. Can J Cardiol 2013 ; 29 : 1165-1172
 
2) Van de Werf, F et al : A Comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves. Am Heart J 2012 ; 163 : 931-937
 
3) Hori, M et al : Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--subanalysis in Japanese population. Circ J 2011 ; 75 : 800-805
 
4) Corey, S et al : Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012 ; 110 : 453-460
 
P.62 掲載の参考文献
1) 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告). 心房細動治療 (薬物) ガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf (2014年2月閲覧)
 
2) 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 循環器疾患における抗凝固・抗血小板療法に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_hori_h.pdf (2014年2月閲覧)
 
3) 循環器病の診断と治療に関するガイドライン (2009-2010年度合同研究班報告). 拡張型心筋症ならびに関連する二次性心筋症の診療に関するガイドライン. 循環器病の診断と治療に関するガイドライン 2011, 2012, 3-79
 
4) 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告). 肥大型心筋症の診療に関するガイドライン (2012年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2012_doi_h.pdf (2014年2月閲覧)
 
5) 循環器病の診断と治療に関するガイドライン (2009年度合同研究班報告). 慢性心不全治療ガイドライン (2010年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2010_matsuzaki_h.pdf (2014年2月閲覧)
 
6) 循環器病の診断と治療に関するガイドライン. 心房細動における抗血栓療法に関する緊急ステートメント. http://www.j-circ.or.jp/guideline/pdf/statement.pdf (2014年2月閲覧)
 
7) Gage, BF et al : Validation of clinical classification schemes for predicting stroke : results from the National Registry of Atrial Fibrillation. JAMA 2001 ; 285 : 2864-2870
 
P.64 掲載の参考文献
1) Yamaguchi, T : Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter prospective randomized trial. Japanese NVAF-Embolism Secondary Prevention Cooperative Study Group. Stroke 2000 ; 31 : 817-821
 
2) Yasaka, M et al : Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation. Intern Med 2001 ; 40 : 1183-1188
 
3) Stroke Prevention in Atrial Fibrillation III randomized clinical trial investigators : Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation : Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996 ; 348 : 633-638
 
4) Lip, GY et al : Fibrin D-dimer and β-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996 ; 94 : 425-431
 
5) Wakita, M et al : Effects of anticoagulation on infarct size and clinical outcome in acute cardioembolic stroke. Angiology 2002 ; 53 : 551-556
 
6) Inoue, H : Under-use of warfarin for patients with nonvalvular atrial fibrillation in Japan. Intern Med 2004 ; 43 : 529-530
 
7) Atarashi, H et al : Present status of anticoagulation treatment in Japanese patients with atrial fibrillation : a report from the J-RHYTHM Registry. Circ J 2011 ; 75 : 1328-1333
 
8) 小谷英太郎ほか : 心房細動に対するワルファリン療法における日本人の至適INR-J-RHYTHM Registryからの報告-. 心電図 2013 ; 33 : 25-31
 
9) Inoue, H et al : Target international normalized ratio value for preventing thromboembolic and hemorrhagic events in Japanese patients with nonvalvular atrial fibrillation. Results of the J-RHYTHM Registry. Circ J 2013 ; 77 : 2264-2270
 
P.70 掲載の参考文献
1) Wolf, PA et al : Atrial fibrillation as an independent risk factor for stroke : The Framingham study. Stroke 1991 ; 22 : 983-988
 
2) Akao, M et al : Current status of clinical background of patients with atrial fibrillation in a community-based survey : The Fushimi AF Registry. J Cardiol 2013 ; 61 : 260-266
 
3) Ogawa, S et al : Optimal treatment strategy for patients with paroxysmal atrial fibrillation : J RHYTHM Study. Circ J 2009 ; 73 : 242-248
 
4) Atarashi, H et al : Present status of anticoagulation treatment in Japanese patients with atrial fibrillation. Circ J 2011 ; 75 : 1328-1333
 
5) Olesen, JB et al : Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation : Nationwide cohort study. BMJ 2011 ; 342 : d124
PubMed
6) Camm, AJ et al : 2012 focused update of the ESC Guidelines for the management of atrial fibrillation : an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012 ; 33 : 2719-2747
 
7) Skanes, AC et al : Focused 2012 update of the canadian cardiovascular society atrial fibrillation guidelines : recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012 ; 28 : 125-136
 
8) イグザレルト適正使用ガイド, 第2版, 2012
 
9) Eikelboom, JW et al : Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation : an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011 ; 123 : 2363-2372
 
10) Granger, CB et al : Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011 ; 365 : 981-992
 
11) Fox, KA et al : Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation and moderate renal impairment. Eur Heart J, 2011 ; 32 : 2387-2394
 
P.72 掲載の参考文献
1) Fang, MC et al : Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007 ; 120 : 700-705
 
2) Yasaka, M et al : Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 2005 ; 115 : 455-459
 
3) van Ryn, J et al : Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor : interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010 ; 103 : 1116-1127
 
4) Heidbuchel, H et al : European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with nonvalvular atrial fibrillation. Europace 2013 ; 15 : 625-651
 
P.74 掲載の参考文献
1) Heidbuchel, H et al : European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with nonvalvular atrial fibrillation. Europace 2013 ; 15 : 625-651
 
2) 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 循環器疾患における抗凝固・抗血小板療法に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_hori_h.pdf (2014年2月閲覧).
 
3) 藤本一眞ほか : 抗血栓薬服用者に対する消化器内視鏡診療ガイドライン. 日本消化器内視鏡学会雑誌 2012 ; 54 : 2075-2102
 
4) Ortel, TL : Perioperative management of patients on chronic antithrombotic therapy. Blood 2012 ; 120 : 4699-4705
 
5) Garcia, DA et al : Anticoagulation, novel agents, and procedures : can we pardon the interruption? Circulation 2012 ; 126 : 255-257
 
6) Ogawa, S et al : Antithrombotic therapy in atrial fibrillation : evaluation and positioning of new oral anticoagulant agents. Circ J 2011 ; 75 : 1539-1547
 
7) Levy, JH et al : Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology 2013 ; 118 : 1466-1474
 
8) Garcia, DA et al : Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 2008 ; 168 : 63-69
 
P.76 掲載の参考文献
1) Schomig, A et al : Triple antithrombotic management after stent implantation : when and how? Heart 2009 ; 95 : 1280-1285
 
2) Leon, MB et al : A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998 ; 339 : 1665-1671
 
3) 循環器病の診断と治療に関するガイドライン. 安定冠動脈疾患における待機的PCIのガイドライン (2011年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2011_fujiwara_h.pdf (2014年2月閲覧)
 
4) Zhao, HJ et al : Triple therapy rather than triple threat. a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest 2011 ; 139 : 260-270
 
5) 循環器病の診断と治療に関するガイドライン. 心房細動治療 (薬物) ガイドライン (2008年改訂版). Circ J 2008 ; 72 (Suppl. IV) : 1581-1638
 
6) 循環器病の診断と治療に関するガイドライン. 循環器疾患における抗凝固・抗血小板療法に関するガイドライン (2009年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2009_hori_h.pdf (2014年2月閲覧)
 
7) Camm, AJ et al : Guidelines for the management of atrial fibrillation : the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010 ; 31 : 2369-2429
 
8) Pisters, R et al : A novel user-friendly score (HASBLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation : The Euro Heart Survey. Chest 2010 ; 138 : 1093-1100
 
P.80 掲載の参考文献
1) Van Gelder, IC et al : Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010 ; 362 : 1363-1373
 
2) Kowey, PR et al : Physician stated atrial fibrillation management in light of treatment guidelines : data from an international, observational prospective survey. Clin Cardiol 2010 ; 33 : 172-178
 
P.87 掲載の参考文献
1) Preliminary report : effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989 ; 321 : 406-412
 
2) 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告). 心房細動治療 (薬物) ガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf (2014年2月閲覧)
 
3) Camm, AJ et al : 2012 focused update of the ESC Guidelines for the management of atrial fibrillation : an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012 ; 33 : 2719-2747
 
4) Wyse, DG et al : A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 ; 347 : 1825-1833
 
5) Van Gelder, IC et al : A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002 ; 347 : 1834-1840
 
6) Roy, D et al : Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008 ; 358 : 2667-2677
 
7) Ogawa, S et al : Optimal treatment strategy for patients with paroxysmal atrial fibrillation : JRHYTHM Study. Circ J 2009 ; 73 : 242-248
 
8) Andrade, JG et al : Antiarrhythmic use from 1991 to 2007 : insights from the Canadian Registry of Atrial Fibrillation (CARAF I and II). Heart Rhythm 2010 ; 7 : 1171-1177
 
9) Fauchier, L et al : Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure. Am J Cardiol 2009 ; 103 : 248-254
 
10) Yamashita, T et al : Heart rate-reducing effects of bisoprolol in Japanese patients with chronic atrial fibrillation : results of the MAIN-AF study. J Cardiol 2013 ; 62 : 50-57
 
11) Nagai, R et al : Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction : comparison of the ultrashort-actingβ1-selective blocker landiolol with digoxin (J-Land study). Circ J 2013 ; 77 : 908-916
 
12) Van Gelder, IC et al : Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010 ; 362 : 1363-1373
 
13) Ishiguro, H et al : Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation. Int Heart J 2008 ; 49 : 281-293
 
P.89 掲載の参考文献
1) 池田隆徳 : 不整脈治療薬としてのβ遮断薬の作用機転と選択基準. β遮断薬のすべて, 萩原俊男ほか編, 先端医学社, 東京, 2009, 278-283
 
P.91 掲載の参考文献
1) McMurray, JJ et al : ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 : The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012 ; 14 : 803-869
 
2) Freeman, JV et al : Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. Circ Cardiovasc Qual Outcomes 2013 ; 6 : 525-533
 
3) Tieleman, RG et al : Digoxin delays recovery from tachycardia-induced electrical remodeling of the atria. Circulation 1999 ; 100 : 1836-1842
 
4) Sticherling, C et al : Effects of digoxin on acute, atrial fibrillation-induced changes in atrial refractoriness. Circulation 2000 ; 102 : 2503-2508
 
5) Farshi, R et al : Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise. J Am Coll Cardiol 1999 ; 33 : 304-310
 
6) Nagai, R et al : Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction : comparison of the ultrashort-actingβ1-selective blocker landiolol with digoxin (J-Land Study). Circ J 2013 ; 77 : 908-916
 
7) Rathore, SS et al : Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003 ; 289 : 871-878
 
P.93 掲載の参考文献
1) 循環器病の診断と治療に関するガイドライン (2010-2011年度合同研究班報告). カテーテルアブレーションの適応と手技に関するガイドライン. 循環器病の診断と治療に関するガイドライン 2012, 2013, 3-67
 
2) Brignole, M et al : 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy : the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace 2013 ; 15 : 1070-1118
 
3) Tracy, CM et al : 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2012 ; 126 : 1784-1800
 
P.98 掲載の参考文献
1) Haissaguerre, M et al : Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998 ; 339 : 659-666
 
2) Haissaguerre, M et al : Electrophysiological breakthroughs from the left atrium to the pulmonary veins. Circulation 2000 ; 102 : 2463-2465
 
3) 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 整脈薬物治療に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_kodama_h.pdf (2014年2月閲覧)
 
4) Wazni, OM et al : Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation : a randomized trial. JAMA 2005 ; 293 : 2634-2640
 
5) Pappone, C et al : A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation : the APAF Study. J Am Coll Cardiol 2006 ; 48 : 2340-2347
 
6) Parkash, R et al : Approach to the catheter ablation technique of paroxysmal and persistent atrial fibrillation : a meta-analysis of the randomized controlled trials. J Cardiovasc Electrophysiol 2011 ; 22 : 729-738
 
7) Weerasooriya, R et al : Catheter ablation for atrial fibrillation : are results maintained at 5 years of follow-up?. J Am Coll Cardiol 2011 ; 57 : 160-166
 
8) Ouyang, F et al : Long-term results of catheter ablation in paroxysmal atrial fibrillation : lessons from a 5-year follow-up. Circulation 2010 ; 122 : 2368-2377
 
9) Calkins, H et al : Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation : two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009 ; 2 : 349-361
 
10) Kubo, M et al : Decreasing incidence of lacunar vs other types of cerebral infarction in a Japanese population. Neurology 2006 ; 66 : 1539-1544
 
11) Bunch, TJ et al : Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. J Cardiovasc Electrophysiol 2011 ; 22 : 839-845
 
12) 循環器病の診断と治療に関するガイドライン (2005年度合同研究班報告). 不整脈の非薬物治療ガイドライン (2006年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2006_kasanuki_h.pdf (2014年2月閲覧)
 
13) 循環器病の診断と治療に関するガイドライン (2010年度合同研究班報告). 不整脈の非薬物治療ガイドライン (2011年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2011_okumura_h.pdf (2014年2月閲覧)
 
14) Cappato, R et al : Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010 ; 3 : 32-38
 
15) D'Ascenzo, F et al : Which are the most reliable predictors of recurrence of atrial fibrillation after transcatheter ablation? : a meta-analysis. Int J Cardiol 2013 ; 167 : 1984-1989
 
16) 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 循環器疾患における抗凝固・抗血小板療法に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_hori_h.pdf (2014年2月閲覧)
 
P.104 掲載の参考文献
1) Haissaguerre, M et al : Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998 ; 339 : 659-666
 
2) Haissaguerre, M et al : Electrophysiological breakthroughs from the left atrium to the pulmonary veins. Circulation 2000 ; 102 : 2463-2465
 
3) 循環器病の診断と治療に関するガイドライン (2010-2011年度合同研究報告). カテーテルアプレーションの適応と手技に関するガイドライン. 循環器病の診断と治療に関するガイドライン 2012, 2013, 3-67
 
4) Yamane, T et al : Segmental pulmonary vein antrum isolation using the "large-size" lasso catheter in patients with atrial fibrillation. Circ J 2007 ; 71 : 753-760
 
5) Packer, DL et al : Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation. J Am Coll Cardiol 2013 ; 61 : 1713-1723
 
6) Sohara, H et al : Feasibility of the radiofrequency hot balloon catheter for isolation of the posterior left atrium and pulmonary veins for the treatment of atrial fibrillation. Circ Arrhythm Electrophysiol 2009 ; 2 : 225-232
 
7) Ouyang, F et al : Complete isolation of left atrium surrounding the pulmonary veins : new insights from the double-Lasso technique in paroxysmal atrial fibrillation. Circulation 2004 ; 110 : 2090-2096
 
8) Takahashi, A et al : Electrical connections between pulmonary veins : implication for ostial ablation of pulmonary veins in patients with paroxysmal atrial fibrillation. Circulation 2002 ; 105 : 2998-3003
 
9) Kumagai, K et al : A new approach for complete isolation of the posterior left atrium including pulmonary veins for atrial fibrillation. J Cardiovasc Electrophysiol 2007 ; 18 : 1047-1052
 
10) Hocini, M et al : Techniques, evaluation, and consequences of linear block at the left atrial roof in paroxysmal atrial fibrillation. a prospective randomized study. Circulation 2005 ; 112 : 3688-3696
 
11) Jais, P et al : Technique and results of linear ablation at the mitral isthmus. Circulation 2004 ; 110 : 2996-3002
 
12) Kuwahara, T et al : Safe and effective ablation of atrial fibrillation : importance of esophageal temperature monitoring to avoid periesophageal nerve injury as a complication of pulmonary vein isolation. J Cardiovasc Electrophysiol 2009 ; 20 : 1-6
PubMed
P.110 掲載の参考文献
1) Calkins, H et al : 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace 2012 ; 14 : 528-606
 
2) Tilz, RR et al : Catheter ablation of long-standing persistent atrial fibrillation : a lesson from circumferential pulmonary vein isolation. J Cardiovasc Electrophysiol 2010 ; 21 : 1085-1093
 
3) Arentz, T et al : Small or large isolation areas around the pulmonary veins for the treatment of atrial fibrillation? : results from a prospective randomized study. Circulation 2007 ; 115 : 3057-3063
 
4) Haissaguerre, M et al : Pulmonary veins in the substrate for atrial fibrillation : the "venous wave" hypothesis. J Am Coll Cardiol 2004 ; 43 : 2290-2292
 
5) Gaita, F et al : Long-term clinical results of 2 different ablation strategies in patients with paroxysmal and persistent atrial fibrillation. Circ Arrhythm Electrophysiol 2008 ; 1 : 269-275
 
6) Knecht, S et al : Left atrial linear lesions are required for successful treatment of persistent atrial fibrillation. Eur Heart J 2008 ; 29 : 2359-2366
 
7) Nademanee, K et al : A new approach for catheter ablation of atrial fibrillation : mapping of the electrophysiologic substrate. J Am Coll Cardiol 2004 ; 43 : 2044-2053
 
8) Li, WJ et al : Additional ablation of complex fractionated atrial electrograms after pulmonary vein isolation in patients with atrial fibrillation : a metaanalysis. Circ Arrhythm Electrophysiol 2011 ; 4 : 143-148
 
9) Nakagawa, H et al : Pathophysiologic basis of autonomic ganglionated plexus ablation in patients with atrial fibrillation. Heart Rhythm 2009 ; 6 (12 Suppl) : S26-S34
 
10) Zhang, Y et al : Efficacy of cardiac autonomic denervation for atrial fibrillation : a meta-analysis. J Cardiovasc Electrophysiol 2012 ; 23 : 592-600
 
11) Kurotobi, T et al : Multiple arrhythmogenic foci associated with the development of perpetuation of atrial fibrillation. Circ Arrhythm Electrophysiol 2010 ; 3 : 39-45
 
12) Lin, D et al : Pulmonary vein antral isolation and nonpulmonary vein trigger ablation without additional substrate modification for treating longstanding persistent atrial fibrillation. J Cardiovasc Electrophysiol 2012 ; 23 : 806-813
 
13) Haissaguerre, M et al : Catheter ablation of longlasting persistent atrial fibrillation : clinical outcome and mechanisms of subsequent arrhythmias. J Cardiovasc Electrophysiol 2005 ; 16 : 1138-1147
 
14) O'Neill, MD et al : The stepwise ablation approach for chronic atrial fibrillation--evidence for a cumulative effect. J Interv Card Electrophysiol 2006 ; 16 : 153-167
 
15) Matsuo, S et al : Clinical predictors of termination and clinical outcome of catheter ablation for persistent atrial fibrillation. J Am Coll Cardiol 2009 ; 54 : 788-795
 
16) Machino-Ohtsuka, T et al : Significant improvement of left atrial and left atrial appendage function after catheter ablation for persistent atrial fibrillation. Circ J 2013 ; 77 : 1695-1704
 
P.112 掲載の参考文献
1) Cappato, R et al : Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2010 ; 3 : 32-38
 
2) Ren, JF et al : Increased intensity of anticoagulation may reduce risk of thrombus during atrial fibrillation ablation procedures in patients with spontaneous echo contrast. J Cardiovasc Electrophysiol 2005 ; 16 : 474-477
 
3) Schrickel, JW et al : Incidence and predictors of silent cerebral embolism during pulmonary vein catheter ablation for atrial fibrillation. Europace 2010 ; 12 : 52-57
 
4) Singh, SM et al : Esophageal injury and temperature monitoring during atrial fibrillation ablation. Circ Arrhythm Electrophysiol 2012 ; 5 : e30
 
5) Sacher, F et al : Phrenic nerve injury after atrial fibrillation catheter ablation : characterization and outcome in a multicenter study. J Am Coll Cardiol 2006 ; 47 : 2498-2503
 
P.114 掲載の参考文献
1) Scharf, C et al : European survey on efficacy and safety of duty-cycled radiofrequency ablation for atrial fibrillation. Europace 2012 ; 14 : 1700-1707
 
2) Tilz, RR et al : Catheter ablation of long standing persistent atrial fibrillation : 5-year outcomes of the Hamburg Sequential Ablation Strategy. J Am Coll Cardiol 2012 ; 19 : 1921-1929
 
3) Gaita, F et al : Long-term clinical result of 2 different ablation strategies in patients with paroxysmal and persistent atrial fibrillation. Circ Arrhythm Electrophysiol 2008 ; 1 : 269-275
 
4) Gerstenfeld, EP et al : Incidence and location of focal atrial fibrillation triggers in patients undergoing repeat pulmonary vein isolation : implications for ablation strategies. J Cardiovasc Electrophysiol 2003 ; 14 : 685-690
 
P.119 掲載の参考文献
1) Maisel, WH et al : Atrial fibrillation in heart failure : epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003 ; 91 : 2D-8D
 
2) Dries, DL et al : Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction : a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998 ; 32 : 695-703
 
3) Wang, TJ et al : Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality : The Framingham heart study. Circulation 2003 ; 107 : 2920-2925
 
4) Wyse, DG et al : A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 ; 347 : 1825-1833
 
5) Roy, D et al : Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008 ; 358 : 2667-2677
 
6) Chen, MS et al : Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol 2004 ; 43 : 1004-1009
 
7) Hsu, LF et al : Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004 ; 351 : 2373-2383
 
8) Gentlesk, PJ et al : Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2007 ; 18 : 9-14
 
9) Khan, MN et al : Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008 ; 359 : 1778-1785
 
10) Choi, AD et al : Ablation vs medical therapy in the setting of symptomatic atrial fibrillation and left ventricular dysfunction. Congest Heart Fail 2010 ; 16 : 10-14
PubMed
11) MacDonald, MR et al : Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction : a randomised controlled trial. Heart 2011 ; 97 : 740-747
 
12) Jones, DG et al : A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 2013 ; 61 : 1894-1903
 
13) Dagres, N et al : Catheter ablation for atrial fibrillation in patients with left ventricular systolic dysfunction. A systematic review and meta-analysis. J Card Fail 2011 ; 17 : 964-970
 
14) Machino-Ohtsuka, T et al : Significant improvement of left atrial and left atrial appendage function after catheter ablation for persistent atrial fibrillation. Circ J 2013 ; 77 : 1695-1704
 
15) Machino-Ohtsuka, T et al : Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction. J Am Coll Cardiol 2013 ; 62 : 1857-1865
 
16) Marrouche, NF et al : Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation (CASTLE-AF) -study design. Pacing Clin Electrophysiol 2009 ; 32 : 987-994
 
P.123 掲載の参考文献
1) Santangeli, P et al : Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications : evidence from a meta-analysis. Circ Arrhythm Electrophysiol 2012 ; 5 : 302-311
 
2) Cappato, R et al : Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol 2009 ; 53 : 1798-1803
 
3) Kaseno, K et al : Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Circ J 2012 ; 76 : 2337-2342
 
4) Calkins, H et al : 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace 2012 ; 14 : 528-606
 
5) Inoue, K et al : National survey of catheter ablation for atrial fibrillation : The Japanese catheter ablation registry of atrial fibrillation (J-CARAF). J Arrhythmia 2013 ; 29, 221-227
 
6) Bunch, TJ et al : Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. Heart Rhythm 2013 ; 10 : 1272-1277
 
7) Hindrics, G et al : Perception of atrial fibrillation before and after catheter ablation : relevance of asymptomatic arrhythmia recurrence. Circulation 2005 ; 112 : 307-313
 
8) Roux, JF et al : Antiarrhythmics after ablation of atrial fibrillation (5A Study). Circulation 2009 ; 120 : 1036-1040
 
9) Rostock, T et al : Atrial fibrillation begets atrial fibrillation in the pulmonary veins : on the impact of atrial fibrillation on the electrophysiological properties of the pulmonary veins in humans. J Am Coll Cardiol 2008 ; 51 : 2153-2160
 
10) Tojo, H et al : Hybrid therapy with pilsicainide and pulmonary vein isolation for atrial fibrillation. Circ J 2005 ; 69 : 1503-1507
 
11) Rordorf, R et al : Pharmacological therapy following catheter ablation of atrial fibrillation. J Cardiovasc Med (Hagerstown) 2012 ; 13 : 9-15
 
12) Inoue, K et al : Discontinuation of anti-arrhythmic drugs in patients receiving hybrid therapy consisting of catheter ablation and bepridil for persistent atrial fibrillation. J Arrhythmia 2012 ; 28 : 170-174
 
13) Koyama, T et al : Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation. J Am Coll Cardiol 2010 ; 56 : 1463-1472
 
P.125 掲載の参考文献
1) Uchiyama, T et al : Six-year follow-up catheter ablation in paroxysmal atrial fibrillation. Circ J 2013 ; 77 : 2722-2727
 
2) Ouyang, F et al : Long-term results of catheter ablation in paroxysmal atrial fibrillation : lessons from a 5-year follow-up. Circulation 2010 ; 122 : 2368-2377
 
3) Fiala, M et al : A prospective evaluation of haemodynamics, functional status, and quality of life after radiofrequency catheter ablation of long-standing atrial fibrillation. Europace 2014 ; 16 : 15-25
 
4) Rostock, T et al : Long-term single- and multiple-procedure outcome and predictors of success after catheter ablation for persistent atrial fibrillation. Heart Rhythm 2011 ; 8 : 1391-1397
 
5) Tilz, R et al : Catheter ablation of long-standing persistent atrial fibrillation : a lesson from circumferential pulmonary vein isolation. J Cardiovasc Electrophysiol 2010 ; 21 : 1085-1093
 
6) Oral, H et al : Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. J Am Coll Cardiol 2002 ; 40 : 100-104
 
7) Balk, EM et al : Predictors of atrial fibrillation after radiofrequency catheter ablation : a systematic review. J Cardiovasc Electrophysiol 2010 ; 21 : 1208-1216
 
8) Hunter, RJ et al : Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death. Heart 2013 ; 98 : 48-53
 
P.130 掲載の参考文献
1) 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告). 心房細動治療 (薬物) ガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf (2014年2月閲覧)
 
2) Fuster, V et al : ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation : A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) : Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006 ; 114 : e257-e354
 
3) Humphries, KH et al : New-onset atrial fibrillation : sex differences in presentation, treatment, and outcome. Circulation 2001 ; 103 : 2365-2370
 
4) Frick, M et al : Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. Clin Cardiol 2001 ; 24 : 238-244
 
5) Klein, AL et al : Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001 ; 344 : 1411-1420
 
6) Fatkin, D et al : Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation : evidence for 'atrial stunning' as a mechanism of thromboembolic complications. J Am Coll Cardiol 1994 ; 23 : 307-316
 
7) Black, IW et al : Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation. A multicenter study. Circulation 1994 ; 89 : 2509-2513
 
8) Kochiadakis, GE et al : Amiodarone versus propafenone for conversion of chronic atrial fibrillation : results of a randomized, controlled study. J Am Coll Cardiol 1999 ; 33 : 966-971
 
9) Yamashita, T et al : Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms : a multicenter, randomized, placebo-controlled,double-blind study (J-BAF Study). Circ J 2009 ; 73 : 1020-1027
 
10) 栗田隆志 : 抗不整脈薬による心電図異常. 救急医学 2010 ; 34 : 725-730
 
11) Camm, AJ et al : Guidelines for the management of atrial fibrillation : the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010 ; 31 : 2369-2429
 
12) Corley, SD et al : Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004 ; 109 : 1509-1513
 
P.138 掲載の参考文献
1) Wijffels, MC et al : Atrial fibrillation begets atrial fibrillation : a study in awake chronically instrumented goats. Circulation 1995 ; 92 : 1954-1968
 
2) Konings, KT et al : Configuration of unipolar atrial electrograms during electrically induced atrial fibrillation in humans. Circulation 1997 ; 95 : 1231-1241
 
3) Allessie, M et al : Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002 ; 54 : 230-246
 
4) Bosch, RF et al : Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 1999 ; 44 : 121-131
 
5) 抗不整脈薬ガイドライン委員会 : 抗不整脈薬ガイドライン-CD-ROM版 ガイドラインの解説とシシリアンガンビットの概念. ライフメディコム, 東京, 2000
 
6) Kawase, A et al : Widening of the excitable gap and enlargement of the core of reentry during atrial fibrillation with a pure sodium channel blocker in canine atria. Circulation 2003 ; 107 : 905-910
 
7) 芦原貴司ほか : 心房筋リモデリングを考慮したヒト心房細動in silicoモデルにおけるアミオダロンの短期作用と長期作用. Prog Med 2008 ; 28 (Suppl 1) : 562-567
 
8) Fujiki, A et al : Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm. Am J Cardiol 2003 ; 92 : 472-475
 
9) AFFIRM First Antiarrhythmic Drug Substudy Investigators : Maintenance of sinus rhythm in patients with atrial fibrillation : an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003 ; 42 : 20-29
 
10) Komatsu, T et al : Randomized crossover study of the long-term effects of pilsicainide and cibenzoline in preventing recurrence of symptomatic paroxysmal atrial fibrillation : influence of the duration of arrhythmia before therapy. Circ J 2006 ; 70 : 667-672
 
11) Shinagawa, K et al : Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium : insights into the mechanism of the superior efficacy of amiodarone. Circulation 2003 ; 107 : 1440-1446
 
12) Sato, D et al : Bepridil inhibits sub-acute phase of atrial electrical remodeling in canine rapid atrial stimulation model. Circ J 2006 ; 70 : 206-213
PubMed
13) Ashihara, T et al : The role of fibroblasts in complex fractionated electrograms during persistent/permanent atrial fibrillation : implications for electrogrambased catheter ablation. Circ Res 2012 ; 110 : 275-284
 
14) Kohl, P et al : Fibroblast-myocyte connections in the heart. Heart Rhythm 2012 ; 9 : 461-464
 
15) Matsumori, A et al : Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells : a possible mechanism for its effect in heart failure. Circulation 1997 ; 96 : 1386-1389
 
P.143 掲載の参考文献
1) Jais, P et al : Catheter ablation versus antiarrhythmic drugs for atrial fibrillation : the a4 study. Circu lation 2008 ; 118 : 2498-2505
 
2) Wyse, DG et al : A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 ; 347 : 1825-1833
 
3) Roy, D et al : Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008 ; 358 : 2667-2677
 
4) 抗不整脈薬ガイドライン委員会 : 抗不整脈薬ガイドライン-CD-ROM版 ガイドラインの解説とシシリアンガンビットの概念. ライフメディコム, 東京, 2000
 
5) Antzelevitch, C et al : Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol 1994 ; 23 : 259-277
 
6) Aiba, T et al : Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. J Am Coll Cardiol 2005 ; 45 : 300-307
 
7) Drew, BJ et al : Prevention of torsade de pointes in hospital settings : a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010 ; 121 : 1047-1060
 
8) Topilski, I et al : The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias. J Am Coll Cardiol 2007 ; 49 : 320-328
 
9) Aiba, T et al : Electrical remodeling in the failing heart. Curr Opin Cardiol 2010 ; 25 : 29-36
 
P.149 掲載の参考文献
1) 児玉逸雄 : アミオダロンの薬理作用. 不整脈にアミオダロンをどう使うか-新たなエビデンスを加えて-, 新版, 日本心電学会学術諮問委員会編, ライフメディコム, 名古屋, 2010, 9-25
 
2) 志賀剛 : アミオダロン : 日本人における有効性と安全性. 循環器科 2006 ; 59 : 599-604
 
3) Deedwania, PC et al : Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation : observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CJFSTAT). The Department of Veterans Affairs CHFSTAT Investigators. Circulation 1998 ; 98 : 2574-2579
 
4) Roy, D et al : Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000 ; 342 : 913-920
 
5) AFFIRM First Antiarrhythmic Drug Substudy Investigators : Maintenance of sinus rhythm in patinets with atrial fibrillation : an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003 ; 42 : 20-29
 
6) Shiga, T et al : Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure. Circ J 2002 ; 66 : 600-604
PubMed
7) Komatsu T, Tachibana H, Sato Y, et al : Efficacy of amiodarone for preventing the recurrence of symptomatic paroxysmal and persistent atrial fibrillation after cardioversion. Circ J 2007 ; 71 : 46-51
 
8) Yamada, Y et al : Incidence and predictors of pulmonary toxicity in Japanese patients receiving lowdose amiodarone. Circ J 2007 ; 71 : 1610-1616
 
9) 志賀剛 : アミオダロンの臨床使用と注意点. 不整脈にアミオダロンをどう使うか-新たなエビデンスを加えて-, 新版, 日本心電学会学術諮問委員会編, ライフメディコム, 名古屋, 2010, 27-48
 
10) Naganuma, M et al : Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy. J Cardiovasc Pharmacol Ther 2001 ; 6 : 363-367
 
P.151 掲載の参考文献
1) 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 不整脈薬物治療に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_kodama_h.pdf (2014年2月閲覧)
 
P.155 掲載の参考文献
1) Kannel, WB et al : Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation : population-based estimates. Am J Cardiol 1998 ; 82 : 2N-9N
 
2) Kumagai, K et al : Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003 ; 41 : 2197-2204
 
3) Conen, D et al : Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation 2009 ; 119 : 2146-2152
 
4) Okin, PM et al : Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006 ; 296 : 1242-1248
 
5) Yamashita, T et al : Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace 2011 ; 13 : 473-479
 
P.159 掲載の参考文献
1) London, B et al : Omega-3 fatty acids and cardiac arrhythmias : prior studies and recommendations for future research : a report from the National Heart, Lung, and Blood Institute and Office of Dietary Supplements Omega-3 Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop. Circulation 2007 ; 116 : e320-335
 
2) Wu, JH et al : Association of plasma phospholipid long-chain omega-3 fatty acids with incident atrial fibrillation in older adults : the cardiovascular health study. Circulation 2012 ; 125 : 1084-1093
 
3) Saravanan, P et al : Cardiovascular effects of marine omega-3 fatty acids. Lancet 2010 ; 376 : 540-550
 
4) Gronroos, NN et al : Diet and risk of atrial fibrillation-epidemiologic and clinical evidence. Circulation J 2010 ; 74 : 2029-2038
 
5) Nodari, S et al : n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion : a prospective, randomized study. Circulation 2011 ; 124 : 1100-1106
 
6) Kumar, S et al : Long-term omega-3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion. Heart rhythm 2012 ; 9 : 483-491
 
7) Kumar, S et al : Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial mechanical function after reversion of atrial arrhythmias to sinus rhythm : Reversal of tachycardia-mediated atrial cardiomyopathy with fish oils. Heart rhythm 2011 ; 8 : 643-649
 
8) Milberg, P et al : Antiarrhythmic effects of free polyunsaturated fatty acids in an experimental model of LQT2 and LQT3 due to suppression of early afterdepolarizations and reduction of spatial and temporal dispersion of repolarization. Heart rhythm 2011 ; 8 : 1492-1500
 
9) Den Ruijter, HM et al : Acute administration of fish oil inhibits triggered activity in isolated myocytes from rabbits and patients with heart failure. Circulation 2008 ; 117 : 536-544
 
10) Richardson, ES et al : Electrophysiological mechanisms of the anti-arrhythmic effects of omega-3 fatty acids. J Cardiovasc Transl Res 2011 ; 4 : 42-52
 
P.163 掲載の参考文献
1) Nakashima, H et al : Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000 ; 101 : 2612-2617
 
2) Kumagai, K et al : Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003 ; 41 : 2197-2204
 
3) Wachtell, K et al : Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol : the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005 ; 45 : 712-719
 
4) Schaer, BA et al : Risk for incident atrial fibrillation in patients who receive antihypertensive drugs : a nested case-control study. Ann Intern Med 2010 ; 152 : 78-84
 
5) GISSI-AF Investigators : Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009 ; 360 : 1606-1617
 
6) Yamashita, T et al : Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace 2011 ; 13 : 473-479
 
7) ACTIVEI investigators : Irbesartan in patients with atrial fibrillation. N Engl J Med 2011 ; 364 : 928-938
 
8) Fogari, R et al : Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. J Cardiovasc Pharmacol Ther 2012 ; 17 : 34-43
 
9) Galzerano, D et al : A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. J Renin Angiotensin Aldosterone Syst 2012 ; 13 : 496-503
 
10) Kumagai, K et al : The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004 ; 62 : 105-111
 

III 知っておくべき心房細動の知識あれこれ

P.169 掲載の参考文献
1) 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告). 心房細動治療 (薬物) ガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf (2014年2月閲覧)
 
2) Camm, AJ et al : Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010 ; 31 : 2369-2429
 
3) Fuster, V et al : ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation : A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) : Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006 ; 114 : e257-e354
 
4) Kato, T et al : Progressive nature of paroxysmal atrial fibrillation : Observations from a 14-year followup study. Circ J 2004 ; 68 : 568-572
 
5) Van Gelder, IC et al : Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996 ; 156 : 2585-2592
 
6) Hohnloser, SH et al : Rhythm or rate control in atrial fibrillation : Pharmacological Intervention in Atrial Fibrillation (PIAF) : a randomized trial. Lancet 2000 ; 356 : 1789-1794
 
7) Wang, TJ et al : Obesity and the risk of new-onset atrial fibrillation. JAMA 2004 ; 292 : 2471-2477
 
8) Nakanishi, K et al : Peri-atrial epicardial adipose tissue is associated with new-onset nonvalvular atrial fibrillation. Circ J 2012 ; 76 : 2748-2754
 
9) Wong, CX et al : Pericardial fat is associated with atrial fibrillation severity and ablation outcome. J Am Coll Cardiol 2011 ; 57 : 1745-1751
 
10) Mazurek, T et al : Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003 ; 108 : 2460-2466
 
11) Fukui, A et al : Role of leptin in the pathogenesis of angiotensin II-mediated atrial fibrosis and fibrillation. Circ Arrhythm Electrophysiol 2013 ; 6 : 402-409
 
P.172 掲載の参考文献
1) Wijffels, MC et al : Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats : roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. Circulation 1997 ; 96 : 3710-3720
 
2) Allessie, M et al : Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002 ; 54 : 230-246
 
3) Gaspo, R et al : Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation 1997 ; 96 : 4027-4035
 
4) Yamashita, T et al : Short-term effects of rapid pacing on mRNA level of voltage-dependent K (+) channels in rat atrium : electrical remodeling in paroxysmal atrial tachycardia. Circulation 2000 ; 101 : 2007-2014
 
5) Fukaya, H et al : Inhomogenic effect of bepridil on atrial electrical remodeling in a canine rapid atrial stimulation model. Circ J 2008 ; 72 : 318-326
 
6) Fukaya, H et al : Combined effects of up- and downstream therapies on atrial fibrillation in a canine rapid stimulation model. Int J Cardiol 2012 ; 157 : 197-206
 
7) Members of the Sicilian Gambit : New approaches to antiarrhythmic therapy, Part I : emerging therapeutic applications of the cell biology of cardiac arrhythmias. Circulation 2001 ; 104 : 2865-2873
 
8) Yamashita, T et al : Recruitment of immune cells across atrial endocardium in human atrial fibrillation. Circ J 2010 ; 74 : 262-270
 
9) Healey, JS et al : Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. a meta-analysis. J Am Coll Cardiol 2005 ; 45 : 1832-1839
 
10) Niwano, S et al : N-acetylcysteine suppresses the progression of ventricular remodeling in acute myocarditis : studies in an experimental autoimmune myocarditis (EAM) model. Circ J 2011 ; 75 : 662-671
 
P.175 掲載の参考文献
1) Evans, W et al : Lone auricular fibrillation. Br Heart J 1954 ; 16 : 189-194
 
2) 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告). 弁膜疾患の非薬物治療に関するガイドライン (2012年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2012_ookita_h.pdf (2014年2月閲覧)
 
3) 循環器病の診断と治療に関するガイドライン (2010年度合同研究班報告). 不整脈の非薬物治療ガイドライン (2011年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2011_okumura_h.pdf (2014年2月閲覧)
 
4) Ogawa, S et al : Optimal treatment strategy in patients with paroxysmal atrial fibrillation. Circ J 2009 ; 73 : 242-248
 
5) Camm, AJ et al : Atrial tachycardia, flutter, and fibrillation. In ; Electrophysiological disorder of the heart. Elsevier, Philadelphia, 2005, 238-363
 
6) Maron, BJ et al : Epidemiology of hypertrophic cardiomyopathy-related death : revisited in a large non-referral-based patient population. Circulation 2000 ; 102 : 858-864
 
7) 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告). 心房細動治療 (薬物) ガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf (2014年2月閲覧)
 
8) Chao, TF et al : CHADS2 and CHA2DS2-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation. J Am Coll Cardiol 2011 ; 58 : 2380-2385
 
P.177 掲載の参考文献
1) Yamashita, T et al : Relation between aging and circadian variation of paroxysmal atrial fibrillation. Am J Cardiol 1998 ; 82 : 1364-1367
 
2) Ogawa, M et al : Left stellate ganglion and vagal nerve activity and cardiac arrhythmias in ambulatory dogs with pacing-induced congestive heart failure. J Am Coll Cardiol 2007 ; 50 : 335-343
 
3) Tan, AY et al : Neural mechanisms of paroxysmal atrial fibrillation and paroxysmal atrial tachycardia in ambulatory canines. Circulation 2008 ; 118 : 916-925
 
4) Choi, EK et al : Intrinsic cardiac nerve activity and paroxysmal atrial tachyarrhythmia in ambulatory dogs. Circulation 2010 ; 121 : 2615-2623
 
5) Patterson, E et al : Sodium-calcium exchange initiated by the Ca2+ transient : an arrhythmia trigger within pulmonary veins. J Am Coll Cardiol 2006 ; 47 : 1196-1206
 
6) Nakagawa, H et al : Pathophysiologic basis of autonomic ganglionated plexus ablation in patients with atrial fibrillation. Heart Rhythm 2009 ; 6 : S26-S34
 
7) Edgerton, JR et al : Totally thorascopic surgical ablation of persistent AF and long-standing persistent atrial fibrillation using the "Dallas" lesion set. Heart Rhythm 2009 ; 6 : S64-70
 
8) Ogawa, M et al : Cryoablation of stellate ganglia and atrial arrhythmia in ambulatory dogs with pacing-induced heart failure. Heart Rhythm 2009 ; 6 : 1772-1779
 
9) Shen, MJ et al : Continuous low-level vagus nerve stimulation reduces stellate ganglion nerve activity and paroxysmal atrial tachyarrhythmias in ambulatory canines. Circulation 2011 ; 123 : 2204-2212
 
P.182 掲載の参考文献
1) Flgel, KM : From delirium cordis to atrial fibrillation ; historical development of a disease concept. Ann Intern Med 1995 ; 122 : 867-873
 
2) Woeber, KA : Thyrotoxicosis and the heart. N Engl J Med 1992 ; 327 : 94-98
 
3) Forfar, JC et al : Thyrotoxic atrial fibrillation ; an underdiagnosed condition? Br Med J 1982 ; 285 : 909-910
 
4) Castellanos, A, Jr et al : Factors regulating ventricular rate during atrial flutter and fibrillation in preexcitation syndrome. Br Heart J 1973 ; 35 : 811-816
 
5) Montoya, P et al : Ventricular fibrillation in the Wolff-Parkinson-White syndrome. Eur Heart J 1991 ; 12 : 144-150
 
6) Rosado, L et al : Actuarial analysis of patient survival as a function of pacemaker type. Pacing Clin Electrophysiol 1987 ; 10 : 409
 
7) Fuster, V et al : The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981 ; 47 : 525-531
 
8) Koga, Y et al : Prognosis in hypertrophic cardiomyopathy. Am Heart J 1984 ; 108 : 351-359
 
9) Fujii, T et al : Different mechanisms of polyuria and natriuresis associated with paroxysmal supraventricular tachycardia. Am J Cardiol 1991 ; 68 : 343-348
 
P.187 掲載の参考文献
1) Wang, TJ et al : Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality : The Framingham Heart Study. Circulation 2003 ; 107 : 2920-2925
 
2) Tsang, TS et al : Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 2002 ; 40 : 1636-1644
 
3) Shillingford, J et al : Hemodynamic effects of acute myocardial infarction in man. Prog Cardiovasc Dis 1967 ; 9 : 571-593
 
4) Viswanathan, K et al : Effect of cardioversion of atrial fibrillation on improvement in left ventricular performance. Am J Cardiol 2001 ; 88 : 439-441
 
5) Nicod, P et al : Importance of the "atrial kick" in determining the effective mitral valve orifice area in mitral stenosis. Am J Cardiol 1986 ; 57 : 403-407
 
6) Redfield, MM et al : Tachycardia-related cardiomyopathy : a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc 2000 ; 75 : 790-795
 
7) Kieny, JR et al : Increase in radionuclide left ventricular ejection fraction after eardioversion of chronic atrial fibrillation in idiopathic dilated cardio myopathy. Eur Heart J 1992 ; 13 : 1290-1295
 
8) Daoud, EG et al : Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol 1996 ; 78 : 1433-1436
 
9) Wasmund, SL et al : Effect of atrial fibrillation and an irregular ventricular response on sympathetic nerve activity in human subjects. Circulation 2003 ; 107 : 2011-2015
 
10) Natale, A et al : Impact on ventricular function and quality of life of transcatheter ablation of the atrioventricular junction in chronic atrial fibrillation with a normal ventricular response. Am J Cardiol 1996 ; 78 : 1431-1433
 
11) Hardman, SM et al : Postextrasystolic potentiation and its contribution to the beat-to-beat variation of the pulse during atrial fibrillation. Circulation 1992 ; 86 : 1223-1232
 
12) Bonow, RO et al : Atrial systole and left ventricular filling in hypertrophic cardiomyopathy : effect of verapamil. Am J Cardiol 1983 ; 51 : 1386-1391
 
13) Robinson, K et al : Atrial fibrillation in hypertrophic cardiomyopathy : a longitudinal study. J Am Coll Cardiol 1990 ; 15 : 1279-1285
 
14) Rossi, A et al : Natriuretic peptide levels in atrial fibrillation : a prospective hormonal and Dopplerechocardiographic study. J Am Coll Cardiol 2000 ; 35 : 1256-1262
 
15) Santini, M et al : Device-detected atrial tachyarrhythmias predict adverse outcome in real-world patients with implantable biventricular defibrillators. J Am Coll Cardiol 2011 ; 57 : 167-172
 
16) Gasparini, M et al : Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression : the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol 2006 ; 48 : 734-743
 
17) Gasparini, M et al : Long-term survival in patients undergoing cardiac resynchronization therapy : the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J 2008 ; 29 : 1644-1652
 
P.189 掲載の参考文献
1) Ellis, ER et al : Heart failure and tachycardia-induced cardiomyopathy. Curr Heart Fail Rep 2013 ; 10 : 296-306
 
2) Fenelon, G et al : Tachycardiomyopathy : mechanisms and clinical implications. Pacing Clin Electrophysiol 1996 ; 19 : 95-106
 
3) Lishmanov, A et al : Tachycardia-induced cardiomyopathy : evaluation and therapeutic options. Congest Heart Fail 2010 ; 16 : 122-126
 
4) Fujino, T et al : Characteristics of congestive heart failure accompanied by atrial fibrillation with special reference to tachycardia-induced cardiomyopathy. Circ J 2007 ; 71 : 936-940
 
5) Nerheim, P et al : Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 2004 ; 110 : 247-252
 
P.191 掲載の参考文献
1) Marzona, I et al : Increased risk of cognitive and functional decline in patients with atrial fibrillation : results of the ONTARGETand TRANSCEND studies. Can Med Assoc J 2012 ; 184 : E329-E336
 
2) Santangeli, P et al : Atrial fibrillation and the risk of incident dementia : a meta-analysis. Heart Rhythm 2012 ; 9 : 1761-1768
 
3) Flaker, GC et al : Cognitive function and anticoagulation control in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2010 ; 3 : 277-283
 
4) Bunch, TJ et al : Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. J Cardiovasc Electrophysiol 2011 ; 22 : 839-845
 
5) Medi, C et al : Subtle post-procedural cognitive dysfunction after atrial fibrillation ablation. J Am Coll Cardiol 2013 ; 62 : 531-539
 
P.197 掲載の参考文献
1) Wijffels, MC et al : Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995 ; 92 : 1954-1968
 
2) Grogan, M et al : Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992 ; 69 : 1570-1573
 
3) Sumida, T et al : Single-beat determination of Doppler-derived aortic flow measurement in patients with atrial fibrillation. J Am Soc Echocardiogr 2003 ; 16 : 712-715
 
4) Matsukida, K et al : Comparison of transthoracic Doppler echocardiography and natriuretic peptides in predicting mean pulmonary capillary wedge pressure in patients with chronic atrial fibrillation. J Am Soc Echocardiogr 2001 ; 14 : 1080-1087
 
5) Okura, H et al : Tissue Doppler-derived index of left ventricular filling pressure, E/E', predicts survival of patients with nonvalvular atrial fibrillation. Heart 2006 ; 92 : 1248-1252
 
6) Kusunose, K et al : Clinical utility of single-beat E/e' obtained by simultaneous recording of flow and tissue Doppler velocities in atrial fibrillation with preserved systolic function. JACC Cardiovasc Imaging 2009 ; 2 : 1147-1156
 
7) Ha, JW et al : Triphasic mitral inflow velocity with middiastolic filling : clinical implications and associated echocardiographic findings. J Am Soc Echocardiogr 2004 ; 17 : 428-431
 
8) Klein, AL et al : Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001 ; 344 : 1411-1420
 
9) Su, P et al : Occluding the left atrial appendage : anatomical considerations. Heart 2008 ; 94 : 1166-1170
 
P.203 掲載の参考文献
1) 循環器病の診断と治療に関するガイドライン (2010年度合同研究班報告). 不整脈の非薬物治療ガイドライン (2011年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2011_okumura_h.pdf (2014年2月閲覧)
 
2) 井上耕一ほか : 心房細動治療の真髄, 小室一成監修, 奥山裕司編, 中外医学社, 東京, 2012, 145-188
 
3) Knechit, S et al : Left atrial linear lesions are required for successful treatment of persistent atrial fibrillation. Eur Heart J 2008 ; 29 : 2359-2366
 
4) 加藤律史 : 心房細動カテーテルアブレーション, 山根禎一編, メジカルビュー社, 東京, 2013, 62-71
 
5) Dong, J et al : Incidence and predictors of pulmonary vein stenosis following catheter ablation of atrial fibrillation using the anatomic pulmonary vein ablation approach : results from paired magnetic resonance imaging. J Cardiovasc Electrophysiol 2005 ; 16 : 845-852
 
6) Masuda, M et al : The impact of atrial fibrillation ablation on left atrial function : association with baseline left atrial function. Pacing Clin Electrophysiol 2012 ; 35 : 327-334
 
7) Calkins, H et al : 2012 HRS/EHRA/ECAS Expert Concensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation : recommendations for patient selection, procedural techniques, patient management and follo-up, definitions, endpoints and research trial design. Europace 2012 ; 12 : 528-606
 
8) Iguchi, Y et al : Annual incidence of atrial fibrillation and related factors in adults. Am J Cardiol 2010 ; 106 : 1129-1133
 
9) Lemola, K et al : Computed tomographic analysis of the anatomy of the left atrium and the esophagus : implications for left atrial catheter ablation. Circulation 2004 ; 110 : 3655-3660
 
10) Dong, J et al : Integrated electroanatomic mapping with three-dimensional computed tomographic images for real-time guided ablations. Circulation 2006 ; 113 : 186-194
 
P.204 掲載の参考文献
1) 井上博ほか : ビギナーからエキスパートまでのホルター心電図パーフェクト. 中山書店, 東京, 2007
 
2) 斉藤憲ほか : ホルター心電図-基本的知識の整理と新しいみかた-. 医学出版社, 東京, 2005
 
P.208 掲載の参考文献
1) Silvet, H et al : Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 2003 ; 92 : 1124-1127
 
2) Schnabel, RB et al : Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation 2010 ; 121 : 200-207
 
3) Tsuchida, K et al : Brain natriuretic peptide concentrations and the risk of cardiovascular events and death in patients with atrial fibrillation. 76th annual scientific meeting of the Japanese societys society, 071-PJ071
 
4) Chung, MK et al : C-reactive protein elevation in patients with atrial arrhythmias. inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001 ; 104 : 2886-2891
 
5) Bruins, P et al : Activation of the complement system during and after cardiopulmonary bypass surgery : postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997 ; 96 : 3542-3548
 
6) Marott, SC et al : Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population. J Am Coll Cardiol 2010 ; 56 : 789-795
 
7) Sadanaga, T et al : Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol 2010 ; 55 : 2225-2231
 
8) Hijazi, Z et al : High-sensitivity troponin I for risk assessment in patients with atrial fibrillation : insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation 2014 ; 129 : 625-634
 

書評

最近チェックした商品履歴

Loading...